Search research articles
Contact Us
Filters
Showing results (11-20 of 153) with videos related to
Page
of 16
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
June 2, 2012
Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test
Agnieszka Pałucha-Poniewiera, Andrzej Pilc
Expert Opinion on Drug Discovery
|
July 14, 2016
Glutamate-Based Drug Discovery for Novel Antidepressants
Agnieszka Pałucha-Poniewiera, Andrzej Pilc
Pharmacotherapy
|
March 24, 2016
Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland
Ewa Stawowczyk, Paweł Kawalec, Andrzej Pilc
Plos One
|
August 6, 2016
Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
Ewa Stawowczyk, Paweł Kawalec, Andrzej Pilc
Frontiers in Pharmacology
|
June 27, 2018
Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
Polish Journal of Pharmacology
|
January 22, 2005
Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms
Agnieszka Pałucha, Piotr Brański, Andrzej Pilc
Plos One
|
May 2, 2015
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Joanna Kryst, Paweł Kawalec, Andrzej Pilc
Pharmacotherapy
|
June 18, 2016
Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis
Paweł Moćko, Paweł Kawalec, Andrzej Pilc
Pharmacological Reports : PR
|
October 1, 2016
Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis
Paweł Moćko, Paweł Kawalec, Andrzej Pilc
Pharmacoeconomics
|
April 19, 2018
Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
Page
of 16
Search research articles
Search
Showing results (11-20 of 153) with videos related to
Sort By:
Page
of 16
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
June 2, 2012
Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test
Agnieszka Pałucha-Poniewiera, Andrzej Pilc
Expert Opinion on Drug Discovery
|
July 14, 2016
Glutamate-Based Drug Discovery for Novel Antidepressants
Agnieszka Pałucha-Poniewiera, Andrzej Pilc
Pharmacotherapy
|
March 24, 2016
Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland
Ewa Stawowczyk, Paweł Kawalec, Andrzej Pilc
Plos One
|
August 6, 2016
Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
Ewa Stawowczyk, Paweł Kawalec, Andrzej Pilc
Frontiers in Pharmacology
|
June 27, 2018
Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
Polish Journal of Pharmacology
|
January 22, 2005
Selective mGlu5 receptor antagonist MTEP attenuates naloxone-induced morphine withdrawal symptoms
Agnieszka Pałucha, Piotr Brański, Andrzej Pilc
Plos One
|
May 2, 2015
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Joanna Kryst, Paweł Kawalec, Andrzej Pilc
Pharmacotherapy
|
June 18, 2016
Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis
Paweł Moćko, Paweł Kawalec, Andrzej Pilc
Pharmacological Reports : PR
|
October 1, 2016
Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis
Paweł Moćko, Paweł Kawalec, Andrzej Pilc
Pharmacoeconomics
|
April 19, 2018
Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
Page
of 16